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ABSTRACT  
 
Purpose. To compare results of population PK analyses obtained with a full empirical 
design (FD) and an optimal sparse design (MD) in a Drug-Drug Interaction (DDI) study 
aiming to evaluate the potential CYP3A4 inhibitory effect of a drug in development, SX, 
on a reference substrate, midazolam (MDZ). Secondary aim was to evaluate the 
interaction of SX on MDZ in the in vivo study. 
Methods. To compare designs, real data were analysed by population PK modelling using 
either FD or MD with NONMEM FOCEI for SX and with NONMEM FOCEI and 
MONOLIX SAEM for MDZ. When applicable a Wald’s test was performed to compare 
model parameter estimates, such as apparent clearance (CL/F), across designs. To 
conclude on the potential interaction of SX on MDZ PK, a Student paired test was 
applied to compare the individual PK parameters (i.e. log(AUC) and log(C
max
)) obtained 
either by a non-compartmental approach (NCA) using FD or from empirical Bayes 
estimates (EBE) obtained after fitting the model separately on each treatment group using 
either FD or MD. 
Results. For SX, whatever the design, CL/F was well estimated and no statistical 
differences were found between CL/F estimated values obtained with FD (CL/F = 8.2 
L/h) and MD (CL/F = 8.2 L/h). For MDZ, only MONOLIX was able to estimate CL/F 
and to provide its standard error of estimation with MD. With MONOLIX, whatever the 
design and the administration setting, MDZ CL/F was well estimated and there were no 
statistical differences between CL/F estimated values obtained with FD (72 L/h and 40 
L/h for MDZ alone and for MDZ with SX, respectively) and MD (77 L/h and 45 L/h for 
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MDZ alone and for MDZ with SX, respectively). Whatever the approach, NCA or 
population PK modelling, and for the latter approach, whatever the design, MD or FD, 
comparison tests showed that there was a statistical difference (p<0.0001) between 
individual MDZ log(AUC) obtained after MDZ administration alone and co-administered 
with SX. Regarding C
max
, there was a statistical difference (p<0.05) between individual 
MDZ log(C
max
) obtained under the 2 administration settings in all cases, except with the 
sparse design with MONOLIX. However, the effect on C
max
 was small. Finally, SX was 
shown to be a moderate CYP3A4 inhibitor, which at therapeutic doses increased MDZ 
exposure by a factor 2 in average and almost did not affect the C
max
. 
Conclusion. The optimal sparse design enabled the estimation of CL/F of a CYP3A4 
substrate and inhibitor when co-administered together and to show the interaction leading 
to the same conclusion than the full empirical design. 
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INTRODUCTION 
Metabolic drug-drug interactions (DDIs) have recently led to prescribing restrictions, 
non-approval of drugs and withdrawal from the market by regulatory agencies (1, 2). 
Thus, the evaluation of the potential risk of metabolic DDI is of high importance within 
the pharmaceutical industry in order to improve safety but also reduce the attrition rate of 
new drugs. According to the guidance for industry from the Food and Drug 
Administration (FDA) (3) dealing with drug interaction studies (Study Design, Data 
Analysis and Implications for Dosing and Labeling), “ (…) drug development should 
follow a sequence in which early in vitro and in vivo investigations can either fully 
address a question of interest or provide information to guide further studies. Optimally, a 
sequence of studies could be planned, moving from in vitro studies to in vivo human 
studies, including those employing special study designs and methodologies where 
appropriate. Indeed, in many cases, negative findings from early in vitro and early 
clinical studies allow to eliminate the need for later clinical investigations”. In this 
context, the aim of this work was to evaluate a global strategy to design early clinical 
DDI studies using only early in vitro study results. 
 
Based on early in vitro study results, a DDI study was planned to evaluate the potential 
inhibitory effect of a phase I compound from Servier research (called SX in the present 
paper) on a reference CYP3A4 substrate, midazolam (MDZ). At this stage of SX 
development, only in vitro information was available regarding the potential DDI and the 
goal for the pharmacokinetic (PK) department was to determine the design of the in vivo 
DDI study, such as the sampling time design. 
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To achieve this goal, a global approach including physiologically based pharmacokinetic 
(PBPK) model predictions, population PK modelling and multiresponse optimal design, 
was applied to advise an optimal sampling time schedule. Methods and results from this 
study are presented in a joint paper (4). A full empirical design (FD) in which the optimal 
sampling times were included was used in the clinical trial. The FD contained 11 and 13 
sampling times for MDZ and SX, respectively, whereas the MD had only 5 joint 
sampling times for both drugs. 
 
To evaluate if this global approach could be applied in drug development, the main 
objective of the present work was to analyse real data by population PK modelling using 
either FD or MD and then to compare population PK parameters between the two 
designs. Secondary objectives were to evaluate the potential metabolism interaction of 
SX on MDZ, and to compare observations to PBPK predictions. 
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MATERIAL AND METHODS 
 
Study design of the DDI clinical trial 
The study was conducted in 12 Caucasian male healthy volunteers aged between 18 and 
40 years (inclusive), with a weight between 50 kg and 100 kg and a Body Mass Index 
(BMI) less than or equal to 28 kg/m² (BMI= Weight (kg)/Height
2
 (m
2
)). All subjects gave 
informed written consent to participate in the study. 
Subjects were hospitalized in the clinical unit from the morning of day 0 (D0) to the 
morning of D8 remaining under permanent medical and nursing supervision. Treatments 
prohibited in the 4 weeks before inclusion and during the study were any treatment which 
could lead to induction or inhibition of hepatic microsomial enzymes P450 3A4 (such as 
ketoconazole and other antifungal azole derivatives, macrolides antibiotics, cisapride, 
cimetidine, omeprazole, tricyclic antidepressant drugs, sildenafil, phenobarbital). 
Grapefruit consumption (juice or fruit) was stopped at least 2 weeks before inclusion of 
subjects and during the study. 
Before drug administration, the subjects were fasting since the previous evening. Study 
drugs were administered with a standard glass of still water (180 ml) and a standard meal 
was allowed no sooner than 2 hours after drug administration.  
On D1, the 12 subjects received a single dose of MDZ (7.5 mg, per os) in order to assess 
its PK after administration of MDZ alone. From D2, SX was administered twice a day to 
reach approximately steady-state (SS) at D6 (96 h after first SX dose). On D6, 2 hours 
after the first daily dose of SX, a single dose of MDZ (7.5 mg, po) was administered in 
order to reach maximal concentrations (C
max
) at the same time for both compounds. SX 
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was administered once again on D6, 12h after the morning SX dose (Study design 
schema in Fig. 1).  
For PK assessment of MDZ, the sampling times were as follows: on D1, prior to MDZ 
administration (H0) and 15min, 30min, 1h, 2h, 3h, 4h, 5h30min, 8h30min, 10h30min, 
12h30min and 22h after D1 MDZ administration; on D6, the sampling times were the same 
as those on D1. This full sampling design with 11 sampling times (without taking into 
account the predose sample) each day was called MDZ FD. 
 
For PK assessment of SX, the sampling times were as follows: on D6, prior to the first 
daily dose of SX (H0) and 40min, 1h, 2h, 2h15min, 2h30min, 3h, 4h, 5h, 6h, 7h30min, 
10h30min and 12h after D6 morning SX administration, and then 30min, 40min, 
2h30min, 4h, 6h, 7h30min and 12h after the second daily dose of SX. This full sampling 
design with 13 sampling times (including the predose sample) over the first daily dose 
interval was called SX FD. Amongst these 13 sampling times, 8 were the same as those 
of MDZ FD. 
 
A multiresponse optimal design approach has been previously performed (4) to determine joint 
optimal sampling times for both MDZ and SX. Thus, among the sampling times of the full 
sampling design, the 5 joint optimal sampling times each day determined previously by a 
multiresponse design approach were as follows: on D1, 15min, 1h, 5h30min, 10h30min and 
22h after D1 MDZ administration; on D6, 2h15min, 3h, 7h30min, 12h30min and 24h after the 
 8
first daily dose of SX, which corresponds to15min, 1h, 5h30min, 10h30min and 22 h after D6 
MDZ administration. 
Thus, for MDZ, the 5 optimal sampling times were the same over the 2 periods (D1 and D6), 
and by definition they were the same for SX on D6. This optimal sparse sampling time 
design was denoted MD (for multiresponse design) throughout the paper. 
 
Population PK modelling  
To analyze observed data of the clinical trial by population PK modelling, models 
previously developed from PBPK simulations were directly applied and PK model 
parameters were estimated. See the first part of this work (4) for the details about 
building and evaluation of the population PK models built from PBPK simulated data.  
 
Briefly, the SX population PK model was a two-compartment model with a first-order 
absorption constant (k
a
) which was fixed. Estimated fixed-effect parameters were the 
apparent elimination clearance (CL/F), the apparent central compartment volume (V
c
/F), 
the apparent distribution clearance (Q/F) and the apparent peripheral volume (V
p
/F). 
Exponential random-effects were added on all fixed-effect parameters to describe inter-
individual variability (IIV) and a correlation between the random variables of CL/F and 
V
c
/F was estimated. The residual error model was a combined (additive and proportional) 
error model in which the additive part was fixed. SX parameter estimates from PBPK 
simulations are in the Table VIII of the first part of this work (4). 
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For MDZ the population PK model was a two-compartment model with a zero-order 
absorption constant. Estimated fixed-effect parameters were CL/F, Vc/F, Q/F, Vp/F and 
the duration of the absorption (T
k0
). Exponential random-effects were added on all fixed-
effect parameters to describe IIV and a correlation between the random variables of CL/F 
and Vc/F was estimated. The residual error model was a combined (additive and 
proportional) error model in which the additive part was fixed. MDZ parameter estimates 
from PBPK simulations are in Table IX of the first part of this work (4). 
 
The population PK models were applied separately to fit SX and MDZ observed 
concentration-time profiles obtained in the clinical trial from either FD or MD. For MDZ, 
the MDZ model was applied to observed PK data of both administration settings (without 
and with SX co-administration) but each occasion was analysed separately. Population 
PK parameters were estimated using NONMEM (5) with the FOCEI (First Order 
Conditional Estimation with Interaction) method. When, the minimization was not 
successful or when the covariance step was not obtained in NONMEM with FOCEI, 
population PK parameters were estimated using MONOLIX version 2.1 with the SAEM 
(Stochastic Approximation version of the Expectation Maximization algorithm) method. 
MONOLIX (www.monolix.org) is a new software dedicated to the analysis of non-linear 
mixed effect models developed by Lavielle and Mentré (6). The algorithm used in this 
software combines the SAEM algorithm with a Markov Chain Monte Carlo procedure. 
The convergence of this algorithm and its good statistical properties have been proven 
and published (7, 8, 9, 10). The algorithm is fast and efficient and converges in situations 
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where other reference methods (including NONMEM) do not. It has already been used 
with success for different PK and PK/PD (Pharmacodynamic) applications (6, 11). 
 
SX and MDZ population PK parameter estimates obtained with MD were compared 
statistically to those obtained with FD using a Wald test (p<0.05). For each parameter, we 
tested whether the difference between the estimates obtained with each design, FD and 
MD, was statistically significant using the following Wald statistic (12): 
( ) ( )22 MDFD
MDFD
SESE
w
ψψ
ψψ
+
−
=  (Equation 1) 
where ψFD and ψMD are the population PK estimates obtained using FD and MD, 
respectively, and, SE(ψFD) and SE(ψMD) are the standard error of estimation of the 
corresponding population PK parameter using FD and MD, respectively. Asymptotically, 
maximum likelihood estimators follow a normal distribution. Therefore, under H0 (null 
hypothesis), w should follow a normal distribution with a mean equals to 0 and a variance 
equals to 1 (N(0,1)) and can be compared to the corresponding critical value of a N(0,1). 
 
Individual empirical Bayes estimates (EBEs) of the MDZ PK parameters were derived 
from the results in each group independently i.e. for each administration setting, for each 
design and for each estimation method. 
 
Non-compartmental analysis from full design  
Based on the MDZ and SX individual concentration-time profiles obtained in the clinical 
trial with the FD, a non-compartmental approach (NCA) analysis was performed using 
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the method described in the first part of this work (4). PK parameters were calculated for 
each subject, under each administration setting for MDZ (alone or co-administered with 
SX), and for SX after the two SX administrations at D6 (dose interval=12h). Calculated 
parameters are the maximal concentration (C
max
), the area under the curve of 
concentrations over the dose interval (AUCτ) for SX and the area under the curve 
between 0 and the infinity (AUC) for MDZ. Results are expressed as median [minimum-
maximum] values. 
The NCA analysis was performed with WinNonlin
®
 Professional version 3.3 and SAS 
version 8. 
 
Analysis of the potential metabolism interaction: comparison tests 
To study the interaction of SX on MDZ, comparison tests were performed to test the 
difference between MDZ individual PK parameters (i.e. AUC and C
max
) obtained after 
administration of MDZ alone and when co-administered with SX. The Student paired test 
with n-1 degrees of freedom is the usual test for the comparison between the two groups 
of the mean of log(AUC) estimated by NCA. As described by Panhard and Mentré (13, 
14), this test can also be applied to compare the mean log(AUC) between the two 
treatment arms estimated from the individual EBE after fitting the population model 
separately on each treatment group. AUC are derived from CL/F by AUC= D/CL/F 
where D is the dose. Therefore, the Student paired test was applied to compare the 
log(AUC) between the two treatment groups (MDZ alone and MDZ co-administered with 
SX) obtained by NCA using FD but also by population PK modelling using either FD or 
MD. 
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In the same way, Student paired tests were applied to compare the log(C
max
) between the 
two treatment groups for each approach. In the population PK modelling approach, 
individual C
max
 were obtained by simulation (step of 0.1h for time interval). 
 
90% confidence intervals (CI) of geometric means were computed for MDZ AUC and 
C
max
 ratios (AUC
MDZ+SX
/ AUC
MDZ 
and C
max MDZ+SX
/ C
max MDZ
) obtained either by NCA or 
by population PK modelling. 
  
Comparison of in vivo results with PBPK predictions 
PBPK predictions described in the first part of this work (4) were compared with in vivo 
concentration-time profiles observed in the clinical trial. Firstly, for both compounds, 
MDZ and SX, at D1 for MDZ only and D6 for both drugs, median, 5
th
 and 95
th
 
percentiles of PBPK simulated concentration-time profiles were computed and compared 
graphically to observed concentration-time data obtained in the clinical trial. 
 
Secondly, PK parameters previously computed from PBPK predictions by NCA (4) were 
compared to PK parameters obtained by NCA of the in vivo concentrations-time profiles 
observed in the clinical trial. For in vivo data analysis, observed AUC and C
max
 inhibition 
ratios (AUC
MDZ+SX
/ AUC
MDZ 
and C
max MDZ+SX
/ C
max MDZ
) were compared to predicted 
C
max
 and AUC inhibition ratios obtained by PBPK approach.  
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RESULTS 
Analysis of the in vivo data by population PK modelling 
SX population PK model 
The SX population PK model previously developed was applied to data observed in the 
clinical trial with FD and MD. There were 240 and 60 SX concentrations obtained in the 
12 subjects after repeated oral doses of SX (dose interval of 12h for 5 days) in the FD and 
the MD, respectively. 
 
For FD and MD, SX parameter estimates with their relative standard errors (RSE%) 
obtained with NONMEM are in Table I (a). Using NONMEM, the minimization was 
successful and the covariance step was obtained for the 2 designs with the FOCEI 
method. With the FD, parameters were well estimated (RSE% were less than or equal to 
16% for fixed-effect parameters, except for Q/F for which RSE was 28%). With MD, 
RSEs were higher than with FD (between 5 and 64% for fixed-effect parameters). SX 
CL/F was very well estimated whatever the design as CL/F RSEs were 6 and 5% with FD 
and MD, respectively. There were no statistical differences (p<0.05, Wald’s test) between 
parameters estimated using FD and MD, except for the estimates of V
p
/F and of the 
proportional part of the residual error. The difference of estimates between the two 
designs was high only for V
p
/F. This could be due to the FOCEI algorithm in NONMEM, 
which stopped in a local minimum. 
 
MDZ population PK model 
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The MDZ population PK model previously developed was applied to observed data when 
MDZ was given alone (D1) or co-administered with SX (D6) using FD or MD. 
There were 142 and 58 MDZ concentrations obtained in the 12 subjects after a single 
7.5mg MDZ oral dose administration with or without SX co-administration in the FD and 
the MD, respectively.  
 
MDZ parameter estimates with their relative standard errors (RSE%) obtained with 
NONMEM and MONOLIX, are in Table I (b) for FD and MD, and for the two 
administration settings, with or without SX co-administration. Fits of MDZ 
concentration-time profiles after administration of a single dose of MDZ (7.5mg, per os) 
alone and co-administered with SX, obtained with MONOLIX using the optimal sparse 
design (MD) are displayed in Fig. 2 for a typical subject. 
 
Using NONMEM, the minimization was successful for 3 out of the 4 population PK 
analyses of MDZ using the FOCEI method. The minimization was not successful for the 
sparse sampling time design, MD, when MDZ was co-administered with SX. The run 
was terminated due to rounding errors (error 134 in NONMEM), but parameter estimates 
were close to those obtained with the full sampling time design, FD. Moreover, for MD, 
the covariance step was not obtained when MDZ was administered alone. For all these 
analyses, only IIV on CL/F and V
c
/F were estimated. 
With FD, whatever the administration setting, with or without SX co-administration, 
parameters were well estimated (less than or equal to 21% for fixed-effect parameters). 
With MD, the accuracy of estimation was not obtained. Thus, with NONMEM, parameter 
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estimates were not compared across designs, as the covariance step was not obtained with 
MD (Wald’s test not applicable). Therefore, MONOLIX was used in order to try to 
obtain parameter estimates with their standard errors of estimation for the 4 population 
analyses.  
Using MONOLIX, convergence was obtained in the 4 MDZ population analyses. Only 
IIV on CL/F and V
c
/F were estimated, except for MD without co-administration of SX 
for which IIV was also estimated on T
k0
 (absorption duration of the zero-order absorption 
constant). 
RSE (%) given by MONOLIX were always obtained and were always higher than those 
given by NONMEM (when obtained). For FD, RSEs were between 11 and 34% for 
fixed-effect parameters. RSEs were higher for MD than for FD, and particularly much 
higher for V
p
/F and Q/F. However, CL/F were always adequately estimated with MD 
whatever the administration setting. With MONOLIX, there were no statistical 
differences (p<0.05, Wald’s test) between parameters estimated using FD and MD. 
 
With FD, MDZ inhibition ratios of CL/F (CL/F
MDZ alone
 /CL/F
MDZ+SX 
) were 1.9 and 1.8 
with NONMEM and MONOLIX, respectively, and with MD, they were 2.0 and 1.7 with 
NONMEM and MONOLIX, respectively. Whatever the design and the estimation 
method used, MDZ CL/F inhibitory ratios were in the same range and led to the 
conclusion of a moderate interaction between the two drugs. MDZ CL/F was about 2 fold 
smaller with SX co-administration.  
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Results of the analysis of the potential metabolism interaction: comparison tests 
MDZ NCA results are displayed in Table 2. Tests of comparison based on individual 
parameters (i.e. log(AUC) and log(C
max
)) were performed using either individual 
parameters obtained by NCA or individual EBEs assessed by population PK modelling. 
This latter approach was performed with both designs (FD and MD) and for both 
estimation methods (FOCEI in NONMEM and SAEM in MONOLIX). Results are 
displayed in Table II. Whatever the approach, NCA or population PK modelling, AUC of 
MDZ were statistically different (p<0.001) when administered without SX or with SX. 
90% confidence intervals of geometric means of AUC were similar whatever the 
approach and showed that SX can be considered as a moderate CYP3A4 inhibitor. In the 
population PK approach, the same conclusions were obtained whatever the design, MD 
or FD, and whatever the estimation method, FOCEI in NONMEM or SAEM in 
MONOLIX.  
Whatever the approach, NCA or population PK modelling, C
max
 of MDZ were 
statistically different (p<0.05) when administered without SX or with SX, except for the 
MD with MONOLIX. 90% confidence intervals of geometric means of C
max
 were in the 
same range whatever the approach, although for the MD with MONOLIX, the 90%CI 
was slightly lower than for the others. Therefore, clinical conclusions based on C
max
 were 
the same whatever the approach and whatever the design in the population PK modelling 
approach: SX had little effect on MDZ C
max
. 
 
Comparison between PBPK predictions and in vivo results  
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For both compounds, SX and MDZ, and on both periods (D1 for MDZ only and D6 for 
both compounds), medians, 5
th
 and 95
th
 percentiles of PBPK simulated concentration-
time profiles and observed concentration-time data obtained in the clinical trial are 
displayed on Fig. 3 and 4 (a &b). Observed SX concentration-time profiles were well 
predicted by the SX PBPK model (Fig. 3), however the SX PBPK model over-predicted 
the inter-individual variability. The MDZ PBPK model predicted the MDZ 
concentration-time profiles well when MDZ was administered alone (Fig. 4a) but slightly 
under-predicted the MDZ concentration-time profiles when MDZ was co-administered 
with SX (Fig. 4b).  
 
Regarding PK parameters computed by NCA using the full design, SX C
max
 and AUC 
obtained in the in vivo study in 12 subjects after repeated doses were in the range of SX 
C
max
 and AUC predicted by the SX PBPK model in 100 (simulated) subjects. However, 
predicted SX C
max
 and AUC ranges were very wide. Indeed, predicted SX median [min-
max] C
max
 and AUC by the SX PBPK model were 1394 [743-6023] ng/mL and 18721 
[8555-121484] ng.h/mL, respectively, whereas observed SX [min-max] C
max 
were [714-
2296] ng/mL and observed SX median [min-max] AUC were 26647 [18987-53799] 
ng.h/mL.  
After a single dose administration of MDZ (7.5mg, per os), observed MDZ C
max
 and 
AUC obtained in the clinical trial in 12 subjects were quite well predicted by the MDZ 
PBPK model since observed MDZ median [min-max] C
max
 and AUC
 
were 40 [18-77] 
ng/mL and 103 [57-224] ng.h/mL, respectively, and predicted MDZ median [min-max] 
C
max
 and AUC were 43 [21-143] ng/mL and 114 [47-455] ng.h/mL, respectively. 
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After a single dose administration of MDZ (7.5mg per os) co-administered with SX at 
steady-state, observed MDZ C
max
 obtained in the clinical trial in 12 subjects were well 
predicted by the DDI PBPK models (observed C
max
 median [min-max] = 51 [35-134] 
ng/mL, and predicted C
max
 median [min-max] = 52 [25-151] ng/mL). However observed 
inhibitory ratio for C
max
 were slightly under-predicted by the DDI PBPK models 
(observed R
I Cmax
 median [min-max] = 1.3 [0.76-2.6] and predicted R
I Cmax
 median [min-
max] = 1.1 [1.1-1.5]). Observed MDZ AUC were slightly under-predicted by the DDI 
PBPK models (observed AUC median [min-max] = 201 [110-367] ng.h/mL, and 
predicted AUC median [min-max] = 140 [47-455] ng.h/mL). Hence, observed inhibitory 
ratio for AUC were slightly under-predicted by the DDI PBPK models (observed R
I AUC
 
median [min-max] = 1.9 [1.4-2.6] and predicted R
I AUC
 median [min-max] = 1.2 [1.1-
2.1]). 
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DISCUSSION  
A DDI study was planned to assess the potential inhibitory effect of a phase I compound 
(SX) on a reference CYP3A4 substrate, MDZ. This clinical study was optimally 
designed, without any in vivo data, using PBPK predictions, population PK modelling 
and multiresponse design optimization. A first paper (4) described the methods and 
results of PBPK predictions, population PK modelling and sampling time optimization 
with evaluation by simulation. The present paper compared full (FD) and optimal sparse 
(MD) sampling time designs by population PK modelling using real data, analysed the 
results of the clinical trial by population PK modelling and non-compartmental approach, 
and then compared results of the clinical trial with PBPK predictions.  
 
Analysis of the SX in vivo data, using the SX model previously developed, showed that 
even if, as expected, RSEs were higher with the optimal sparse design, SX CL/F was well 
estimated by NONMEM with both designs. There were no statistical differences (p<0.05, 
Wald’s test) between parameters estimated using FD and MD, except for the estimates of 
V
p
/F and of the proportional part of the residual error. Analysis of the MDZ in vivo data, 
using the MDZ model previously developed, showed that MDZ CL/F was adequately 
estimated with both designs whatever the administration setting (without or with SX co-
administration) using MONOLIX. With NONMEM, the covariance step was not obtained 
with the sparse design (MD) and therefore, the standard errors of CL/F estimation were 
not assessed. However, using NONMEM, MDZ CL/F estimates obtained with MD were 
close to those obtained with FD and therefore inhibitory CL/F ratios were 1.9 and 2.0 
with FD and MD, respectively. With MONOLIX, there were no statistical differences 
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(p<0.05, Wald’s test) between parameters estimated using FD and MD and inhibitory 
CL/F ratios were 1.8 and 1.7 with FD and MD, respectively. Thus, whatever the 
estimation method and the design (full or sparse), we concluded that SX is a moderate 
CYP3A4 inhibitor, which given at maximum therapeutic doses reduced the apparent 
clearance of MDZ by half. These results were also in agreement with those obtained by 
non-compartmental analysis since the median inhibition ratio of AUC was 1.9. 
 
Using NONMEM, the minimization was successful and the covariance step was obtained 
in 4 out of 6 runs whereas with MONOLIX, the 6 runs converged and accuracies of 
parameter estimation were always obtained. Moreover MONOLIX (version 2.1) was by 
far faster than NONMEM (version V). 
 
Inter-individual variability was estimated only on MDZ CL/F and V
c
/F whereas the MDZ 
population PK model developed using MDZ PBPK simulations had inter-individual 
variability on all parameters; this is likely due to the small number of subjects (n=12) in 
the clinical trial. The PBPK models correctly predicted the concentration-time profiles of 
SX and MDZ when administered separately, but under-predicted the interaction of SX on 
MDZ. Although the PBPK model did not predict a 2-fold decrease in MDZ CL/F, the 
MDZ population PK model developed from the simulated PBPK MDZ concentration-
time profiles was able to fit the observed data. 
 
In the present work, the analysis of observed PK data by population PK modelling was 
performed by estimating model parameters of the population PK models previously 
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developed with PBPK simulations. As no in vivo PK data were used to develop these 
population PK models, this was a challenge due to a high risk of model misspecification. 
However, whatever the design and the compound, model runs were successful at least 
with MONOLIX and results in terms of fit were satisfactory. Moreover, according to 
usual GOF plots, the models did not suffer from model misspecification except in one 
case, i.e. MDZ co-administered with SX and with the optimal sparse design. Comparison 
of reference model parameter estimates (those obtained from model buildings from 
PBPK simulations) with those obtained from observed PK data showed that both models 
suffered from parameter misspecification. PK modelling results may have been improved 
if models had been built from in vivo data.  
 
Whatever the compound, the design and the software, proportional error estimates of the 
residual error models were much higher with observed data than with PBPK simulations 
and therefore it may be more realistic to increase the noise in the simulated data. 
 
For MDZ CL/F, the expected RSE given by PopDes (15) with MD was around 20% (4), 
which was in agreement with CL/F RSE obtained with MONOLIX (17%) when MDZ 
was administered alone (i.e. no interaction) and not too far from that obtained when MDZ 
was co-administered with SX (29%). Thus, CL/F RSEs obtained with MONOLIX were 
in agreement with expected RSEs given by PopDes (the software used to estimate the 
joint optimal sampling times). For SX CL/F, the expected RSE given by PopDes with 
MD was 31%, which was high in comparison with NONMEM CL/F RSE (5%).  
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Comparisons were performed to test the difference between MDZ PK without and with 
SX co-administration. This was performed on the logarithms of AUC and C
max
 since the 
Food and Drug Administration (16, 17) and the European Agency for the Evaluation of 
Medicinal Product (EMEA) (18, 19) guidelines recommend to test comparison or 
equivalence as the ratio of the geometric means of PK parameters such as the AUC and 
C
max
. AUC and C
max
 are usually estimated by NCA, which is a method that typically uses 
a large number of samples per subject. Since in the present work, we were interested in 
comparing two designs, a full design and an optimal sparse design, on their capability to 
detect a potential interaction between two drugs, data were analyzed by a population 
approach and the same tests were applied on AUC and C
max
 derived from EBE (13, 14). 
Indeed, Panhard and Mentré showed that results of EBE and NCA tests are similar except 
when the number of samples per subject is very low. Thus, NCA tests are applicable 
when the number of sample per subject is large, whereas non-linear mixed-effects 
modelling is very powerful for cross-over studies where the number of samples per 
subject is limited. However, the shrinkage in parameter must be low (less than 20%) to 
apply this method to EBE. As the shrinkage in CL/F was always satisfactory, the method 
based on EBE was applicable to AUC. In only one case, the optimal sparse design with 
MONOLIX when drugs are co-administered, the shrinkage was higher than 20% for one 
parameter, the apparent central volume. Consequently we can have some reserves about 
the method when applied to C
max
 in this case only. 
Regarding AUC, results of NCA and EBE tests were similar with FD whatever the 
estimation method used for the population PK modelling, and results of EBE tests 
performed with the full design were similar to those obtained with the optimal sparse 
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design (MD) with SAEM (MONOLIX) as well as with FOCEI (NONMEM). All 
methods led to the same conclusion with respect to the difference of AUC between the 
two administration settings, without and with SX co-administration. Regarding C
max
, all 
tests concluded to the difference of MDZ C
max
 between the 2 administration settings 
except with the optimal sparse design with MONOLIX. However, the effect on C
max
 was 
smaller than on AUC.  
 
According to the general strategies of drug-drug interaction studies reported in the 
guidance for industry (3), drug development should follow a sequence of studies from in 
vitro studies to in vivo human studies, including those employing special study designs 
and methodologies where appropriate. A complete understanding of the quantitative 
relationship between the in vitro findings and in vivo results of metabolism/drug-drug 
interaction studies is still emerging. Nonetheless, in vitro studies can frequently serve as a 
screening mechanism to rule out the importance of a metabolic pathway and the drug-
drug interactions that could occur through this pathway so that subsequent in vivo testing 
is unnecessary. In the present example, in vitro studies showed a potential inhibitory 
effect of SX on a reference CYP3A4 substrate, MDZ.  
On the one hand, using the current recommended approach, in which the likelihood of an 
in vivo interaction is projected based on the [I]/Ki ratio where [I] represents the mean 
steady-state C
max
 value for total drug (bound plus unbound) following administration of 
the highest proposed clinical dose of the inhibitor, the predicted interaction was 
considered possible but not likely (0.1<[I]/Ki<1) and therefore in vivo evaluation was 
recommended. On the other hand, using a PBPK modelling approach, which allowed the 
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concentration-time profiles of the two co-administered drugs in each tissue of the whole 
body, such as the liver, to be taken into account, the predicted inhibitory AUC ratio was 
1.2 [1.1-2.1] (median [min-max]) and SX was considered as a weak inhibitor of 
CYP3A4. The discrepancy between the two approaches could be due to the high binding 
of SX to plasma proteins, which was taken into account with the PBPK modelling 
approach whereas it was not with the classical recommended approach and also to the use 
of liver concentrations in the PBPK approach. Bearing in mind that drug development 
must be as fast as possible with limited costs and limited investigations in healthy 
volunteers, our objective was to evaluate the global approach used in the present work 
with real data to further apply it to assess DDI directly in patients in phase II studies for 
drugs with weak predicted inhibitory effect (PBPK approach) or for which the predicted 
interaction was possible but not likely (classical approach with 0.1<[I]/Ki<1).  
Although the DDI was slightly under predicted by PBPK predictions, the population PK 
analysis with the optimal sparse design determined from PBPK predictions allowed the 
measurement of the same extent of drug interaction from observed data as the non-
compartmental analysis with the full design. Moreover, the optimal sampling time design 
would allow the use of 12 fewer sampling times for MDZ clearance estimation in 
comparison to the full empirical design and therefore the sparse optimal design could be 
used in phase II studies and limit costs. By performing some DDI studies directly in 
patients, the development could be faster and information could be directly obtained in 
the target population. In the present work, no PK differences were expected between 
healthy volunteers and patients. Nevertheless, the PBPK modelling approach is capable 
to predict patient PK profiles when necessary (19, 20, 21) 
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The present example was particularly challenging as only in vitro data were used to 
perform PBPK predictions, but we could imagine applying this approach just after the 
first dose in man study and therefore including prior knowledge of the drug PK into the 
PBPK model. 
 
In the present example, the maximum therapeutic dose of the inhibitor, the drug in 
development, was known at early stage of the development, and therefore it was possible 
to design a study in agreement with guidelines (i.e. to test the maximum therapeutic dose 
of the inhibitor). This is a very rare case. However this global approach can be applied to 
evaluate the effects of well-know inhibitors on drugs in development (substrate), and 
therefore it is not necessary to know the therapeutic dose of the substrate to use this 
approach. 
 
Lastly, if an interaction is expected between a drug in development (inhibitor/ substrate) 
with a drug (substrate/ inhibitor) likely to be co-administered in the target population, an 
optimal study design with joint sampling times for the two co-administered drugs could 
allow the assessment of the PK DDI and the characterization of the clinical impact of the 
drug interaction in large-scale clinical studies (phase III) by linking the drug exposure to 
potential adverse events. 
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CONCLUSION 
 
For the first time, a global strategy including PBPK predictions, population PK modelling 
and multiresponse optimal design was applied to design a drug-drug interaction study 
without any in vivo prior information. While a first paper (4) described the method to 
design the clinical trial, the present paper analyzed the results of the clinical trial. 
Although, the drug-drug interaction was slightly under predicted by PBPK predictions, 
population PK analysis with the optimal sparse design allowed the assessment of the drug 
interaction equally well as the non-compartmental analysis with the full design. Thus, this 
global approach allows the quantification of the drug-drug interaction with an ethical and 
cost limited design, and can be applied in drug development. This global approach could 
be extended to assessment of DDI in phase II and III clinical trials. 
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Table I (a). SX population PK model parameter estimates using either the FD or the MD 
with NONMEM at day 6 (repeated doses with a dose interval of 12h for 5 days).  
 
Estimate (RSE%) FD MD Wald’s test 
CL/F (L/h) 8.2 (6) 8.2 (5) ns 
V
c
/F (L) 17 (16) 24 (35) ns 
Q/F 
 
(L/h) 8.1 (28) 14 (64) ns 
V
p
/F (L) 1000 (14) 19 (58)  p<0.001 
k
a
 
 
(h
-1
) 0.19 FIXED 0.19 FIXED na 
ω2_CL/F 0.04 (125) 0.04 (56) ns 
ω2_V
c
/F 
0.14 (49) 0.51 (94) ns 
correlation CL/F - V
c
/F -0.035 (0.015) 0.027 (0.081) ns 
Prop (CV%) 26 (8) 20 (11) p=0.048 
Add (ng/mL) 0.2 FIXED 0.2 FIXED na 
ns stands for no statistical difference between parameter estimates obtained with both designs 
(Wald’s test, p<0.05), na stands for not applicable. 
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Table I (b). MDZ population PK model parameter estimates using either the FD or the 
MD with NONMEM and MONOLIX under the 2 administration settings, without and 
with co-administration of SX.  
Without SX With SX 
Estimates (RSE%) 
FD MD Wald’s test FD  MD Wald’s test 
NONMEM  75 (12) 101 (nd)
*
 na 40 (10)
 
50 (nd)
**
 na 
CL/F (L/h) 
MONOLIX  72 (12) 77 (17) ns 40 (11) 45 (29) ns 
NONMEM  150 (20) 178 (nd)
*
 na 110 (14)
 
187 (nd)
**
 na 
V
c
/F 
 
(L) 
MONOLIX  116 (29) 169 (32) ns 125 (15) 181 (16) ns 
NONMEM  23 (21) 85 (nd)
*
 na 10 (12)
 
10 (nd)
**
 na 
Q/F
 
(L/h) 
MONOLIX  30 (30) 20 (68) ns 8 (34) 9 (85) ns 
NONMEM  88 (17) 215 (nd)
*
 na 56 (14)
 
88 (nd)
**
 na 
V
p
/F (L) 
MONOLIX  80 (18) 93 (41) ns 53 (30) 177 (351) ns 
NONMEM  1.1 (6) 1.0 (nd)
*
 na 1.2 (10) 1.0 (nd)
**
 na 
T
k0 
(h) 
MONOLIX  1.2 (16) 1.0 (32) ns 0.8 (12) 1.0 (20) nd 
NONMEM  0.13 (38) 0.09 (nd)
*
 na 0.11 (45)
 
0.089 (nd)
**
 na 
ω2_CL/F 
MONOLIX  0.13 (47) 0.11 (77) ns 0.12 (47) 0.09 (77) ns 
NONMEM  0.37 (32) 0.29 (nd)
*
 na 0.19 (63)
 
0.038 (nd)
**
 na 
ω2_V
c
/F 
MONOLIX  0.46 (49) 0.15 (165) ns 0.12 (60) 0.47 (197) ns 
NONMEM  0.160 (0.076)  0.110 (nd) na 0.110 (0.074) 0.058 (nd) na correlation 
CL/F_V
c
/F  MONOLIX  0.167 (nd) 0.128 (nd) na 0.105 (nd) 0.201 (nd) na 
NONMEM  0 fixed 0 fixed na 0 fixed 0 fixed na 
ω2_ T
k0
 
MONOLIX  0 fixed 0.20 (117) na 0 fixed 0 fixed na 
NONMEM  46 (6) 61 (nd)
*
 na 0.43 (5)
 
0.56 (nd)
**
 na
 
Prop (CV%) 
MONOLIX  43 (8) 56 (15) ns 42 (7) 54 (13) ns 
NONMEM  0.2 fixed 0.2 fixed na 0.2 fixed 0.2 fixed na Add 
(ng/mL) MONOLIX  0.2 fixed 0.2 fixed na 0.2 fixed 0.2 fixed na 
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na stands for not applicable, ns stands for no statistical difference between parameter estimates obtained 
with both designs (Wald’s test, p<0.05), nd stands for not determined,
 *
 stands for run for which the 
covariance step was not obtained, 
**
 stands for run for which the minimization was not successful. ω2_Q/F 
and ω2_V
p
/F were fixed to zero in the model. 
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Table II. Comparison tests based on log (AUC) and log(C
max
) individual parameters 
between groups (MDZ without SX and MDZ co-administered with SX). 
 
  AUC median [min-max] Log(AUC) 
Estimation method Design MDZ alone MDZ with SX Estimate  
[90% CI] of ratio 
Student paired test 
NCA  FD 103 [57-224] 201 [110-367] 1.9 [1.7-2.1] p<0.0001 
FD 98 [55-182] 182 [110-355] 1.9 [1.6-2.1] p<0.0001 NONMEM 
MD 78 [51-123] 143 [99-226] 2.0 [1.8-2.2] p<0.0001 
FD 102 [58-184] 180 [108-344] 1.8 [1.6-2.1] p<0.0001 MONOLIX 
MD 100 [67-166] 155 [110-250] 1.7 [1.6-1.9] p<0.0001 
 
  C
max
 median [min-max] Log(C
max
) 
Estimation method Design MDZ alone MDZ with SX Estimate  
[90% CI] of ratio 
Student paired test 
NCA  FD 40 [18-77] 51 [35-134] 1.3 [1.1-1.7] p=0.0224 
FD 39 [17-70] 50 [34-125] 1.5 [1.1-1.9] p=0.0195 NONMEM 
MD 26 [17-42] 33 [26-45] 1.3 [1.1-1.5] p=0.0063 
FD 42 [18-75] 51 [32-102] 1.3 [1.1-1.7] p=0.0487 MONOLIX 
MD 35 [21-56] 34 [27-48] 1.1 [1.0-1.2] p=0.1935 
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Fig. 1. Study design of the drug-drug interaction clinical trial. MDZ stands for 
Midazolam, SX for a phase I compound, s.d. for single dose and Di for the i
th
 Day of the 
study. 
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Fig. 2 MDZ concentration-time profile in a typical subject after a 7.5 mg MDZ single 
dose administration (top) and after a 7.5 mg MDZ single dose administration given to 2h 
after the first daily dose of SX (bottom). Dots correspond to observed MDZ 
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concentration-time data, lines correspond to individual predicted profiles and dotted lines 
correspond to population predicted profiles. Concentrations used were those measured at 
the optimal sampling times (sparse optimal sampling time design, MD) and modelling 
was performed with MONOLIX version 2.1. 
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Fig. 3. Comparison of observed SX concentration-time data with simulated 
concentration-time profiles obtained using SX PBPK model. Thin dashed lines with dots 
correspond to observed SX concentration-time data, and plain line and both large dotted 
lines correspond to the median and the 5
th
 and 95
th
 percentiles of simulated SX 
concentration-time data, respectively. 
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Fig. 4 Comparison of observed MDZ concentration-time data with simulated 
concentration-time profiles obtained using MDZ PBPK model. These results correspond 
to MDZ concentration-time data after a 7.5mg MDZ single oral dose (top) without SX 
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co-administration, (bottom) with SX co-administration. Thin dashed lines with dots 
correspond to observed MDZ concentration-time data and plain line and both large dotted 
lines correspond to the median and the 5
th
 and 95
th
 percentiles of simulated MDZ 
concentration-time data, respectively. 
 
